Formulation Design and In Vitro Characterization of Etoricoxib Cream for the Treatment of Rheumatoid Arthritis Formulation Design and In-Vitro Characterization of Etoricoxib Cream for the Treatment of Rheumatoid Arthritis
Iranian Journal of Pharmaceutical Sciences,
Vol. 10 No. 1 (2014),
15 January 2014
,
Page 93-104
https://doi.org/10.22037/ijps.v10.40837
Abstract
Non-Steroidal Anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase (COX)-2 inhibitors, have come to play an important role in the pharmacologic management of musculoskeletal disorders. Clinical trials have established the efficacy of etoricoxib in Osteoarthritis, Rheumatoid Arthritis, Acute Gouty Arthritis, Ankylosing Spondylitis, Low back pain, acute postoperative pain, and primary dysmenorrheal. The present research has been undertaken with the aim to develop a novel topical cream formulation of etoricoxib, which would attenuate the gastrointestinal relater toxicities associated with oral administration. Etoricoxib is a highly selective cyclooxygenase‐2 (cox‐2) inhibitor. In the present study, a fixed concentration of Etoricoxib cream (1%) was prepared by using a different combination of Active ingredient and Excipients. To access the efficacy of formulated cream, in vitro evaluation including stability studies, tube extrudes ability, spread ability, pH, viscosity and
rheological properties as well as drug diffusion studies were done. After in vitro evaluation of cream formulations, the formulation was evaluated for the anti‐inflammatory and skin irritation study. The results obtained were encouraging and formulation containing Etoricoxib (1%) exhibited the most satisfying results of all the parameters.
- Anti-Inflammatory
- Cream
- Etoricoxib
- Stability studies
How to Cite
References
[2] Zochling. Non steroidal anti-inflammatory drug use in ankylosing spondylitis—A population-based survey.J Clin Rheumatol (2006)25(6): 794–800.
[3] Hochberg M.C. COX-2 selective inhibitors in the treatment of arthritis: A rheumatologist perspective. Journal of Current Tropical Medicinal Plants (2005) 5(5): 443–448.
[4] Kuorinka I. Standardised Nordic questionnaires for the analysis of musculoskeletal symptoms. Journal of Applied Agronomics (1987) 18(3): 233-237.
[5] Sprig, C. A. Work characteristics, musculoskeletal disorders, and the mediating role of psychological strain: A study of call center employees. J Appl Psychol (2007) 9(5): 1456-1466.
[6] Gatchel R. J., Kishino N. Pain. Musculoskeletal injuries and return to work. Handbook of occupational health psychology, 2 nd edition, Washington, DC:American Psychological Association (2011).
[7] Gallagher S, Heberger J. R. Examining the interaction of force and repetition on musculoskeletal disorder risk. A systematic literature review. Human Factors (2013) 55(1): 108-124.
[8]Valenta C, Wanka M, Heidlas J. Evaluation of novel soya‐lecithin formulations for dermal use containing ketoprofen as a model drug. Journal of Control Release JCR (2000) 63:165‐173.
[9] Rhee Y. Transdermal delivery of ketoprofenusing micro emulsions. International Journal of Pharmaceutics AIP (2001) 2 (3):161‐170.
[10] RiendeauD, Percival MD, Brideau C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.Journal of Pharmacology and Experimental
Therapeutics JPET (2001)296:558–66.
[11] Agrawal NG, Porras AG, Matthews CZ. Single-and multiple-dose pharmacokinetics of etoricoxib a selective inhibitor of cyclooxygenase-2 in man. Journal of Clinical Pharmacology JCP (2003)43:268–76.
[12] M.RaziUllah Khan, Shahid Masood Raza and Musaddique Hussain. Formulation and In-Vitro evaluation of Cream containing Diclofenac Sodium and Curcuma Longa for the Management of Rheumatoid
Arthritis. International Journal of Pharma SciencesIJPS (2014) 4(4): 654-660.
[13] Gupta GD, Gaud RS. Release rate of Tenoxicam from acrypol gels, Journal of Indian Pharmacist (2005)69 – 76.
[14] Chakole CM, Shende MA, Khadatkar SN.Formulation and development of novel combined halobetasol propionate and fusidic acid ointment,International Journal of Chemical Technology Research (2009)1: 103 – 116.
[15]Rathore RPS, NemaRK. Formulation and evaluation of topical gels of Ketoprofen, Asian Journal of Pharmaceutical and Clinical Research (2008)1: 12 –16.
[16] Wood J. H., Catacalos G. Liberman S. V.Adaptation of commercial viscometers for special applications in pharmaceutical rheology-II, Journal of Pharmaceutical Sciences (1993) 52: 375-378.
[17] Umadevi SK. The effect of polymers and permeation enhancers on in vitro release of aceclofenac from topical gel formulations. Biosciences Biotechnology Research Asia (2005) 5(1): 237-244.
[18] Alexander S, Thyangarajapuram N. Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride. International Journal of Pharmaceutical Compounding (2003) 3:34-36.
[19] Nakhat PD, Rathi LG, Yeole PG. Development and evaluation of sorbitanmonostearate organogels of ibuprofen. Indian Drugs (2006) 43 (5): 421‐430.
[20] Kulkarni SK, Jain NK. Pharmacological and pharmacokinetic studies on marketed gel formulations of nimesulide. Indian Drugs (2001) 38 (2): 63‐69.
- Abstract Viewed: 448 times
- IJPS_Volume 10_Issue 1_Pages 93-104 Downloaded: 361 times